Buradasınız

Anasayfa » Content

învitro Perfüze Sıçan Kalbinde Başlangıç Solüsyonu ve Kardiyoplejiye Kaptopril ve Lisinopril îlavesinin Myokard Üzerine Etkileri

Myocardial Effects of Captopril and Lisinopril Addition to the Prime Solution and Cardioplegic Solution on Rat Heart under in vitro Perfusion Conditions

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Aim: We aimed to investigate the myocardial effects of the addition of captopril, a sulphydryl -containing angiotensin converting enzyme (ACE) inhibitor and lisinopril, a non -sulphydryl-containing ACE inhibitor to the prime solution and cardioplegia. Material and Methods: Isolated rat heart model was used for the study. Rats were allocated into three groups: a control group, lisinopril group and captopril group. For all groups, cardioplegic arrest was achieved following 20 minutes of perfusion and 30 minutes of ischemia with con tinuous cardioplegic infusion and 30 min of reperfusion following ischemia were performed. According to study group, lisinopril or captopril were added to the prime solution and cardioplegic solution. Coronary blood flow, cardiac oxygen consumption, CPK, L DH, AST secretions were measured in perfusion and reperfusion periods. Results: Both drugs, compared to the plasebo group, caused statistically significant increase in coronary blood flow during perfusion and reperfusion phases and cardiac oxygen consumpt ion at minute 30 of reperfusion. Conclusions: We concluded that, as ACE inhibitors have an increasing effect on coronary blood flow, they may be used in coronary artery disease cases with high preoperative risk, in hyperthropic myocardium with increased oxygen demand and cases with expected long CPB (cardiopulmonary bypass) durations. We obtained similar results with both drugs, therefore we assume that —SH groups don't play a major role in these effects.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Myokard üzerine akut ve kronik olumlu etkileri bilinen Anjiyotensin Dönüştürücü Enzim (ADE) inhibitörlerinden; -SH grubu içeren kaptopril ile -SH grubu içermeyen lizinopril'in başlangıç solüsyonuna ve kardiyoplejiye ilave edilmesinin myokard üzerine etkilerinin incelenmesi Gereç ve Yöntem: Çalışma izole perfüze sıçan kalbinde gerçekleştirildi. Sıçanlar; kontrol grubu, lizinopril g rubu ve kaptopril grubu olarak üç gruba ayrıldı. Tüm gruplarda 20 dakika perfüzyon, kardiyoplejik arrest, 30 dakika iskemi ve 30 dakika reperfüzyon yapıldı. İlaç gruplarında başlangıç solüsyonuna ve kardiyoplejiye, gruba göre lizinopril veya kaptopril eklendi. Tüm gruplarda perfüzyon ve reperfüzyon döneminde koroner kan akımı, kalbin oksijen tüketimi, CPK, LDH, AST enzim sekresyonu ölçüldü. Bulgular: Her iki ilaç da kontrol grubuna göre, perfüzyon ve reperfüzyon döneminde koroner kan akımını ve reperfuzyonun 30. dakikasında kalbin oksijen tüketimini istatistiksel olarak anlamlı arttırdı. Sonuç: ADE inhibitörlerinin koroner kan akımını arttırıcı etkileri nedeniyle; preoperatif riskli koroner arter hastalarında, oksijen ihtiyacı artmış hipertrofik myokardda v e KPB (kardiopulmoner bypass) süresi uzun sürmesi beklenen vakalarda kullanılabilecekleri kanısına vardık. Her iki ilaçla da benzer sonuçlar almamız, -SH grubunun bu etkilerde rolü olmadığını veya rolü olsa bile tek mekanizma olmadığı düşüncesine bizi ulaş tırdı.
FULL TEXT (PDF): 
PDF icon arastirmax-invitro-perfuze-sican-kalbinde-baslangic-solusyonu-kardiyoplejiye-kaptopril-lisinopril-ilavesinin-myokard-uzerine-etkileri.pdf
  • 4
175-180
  • Turkish

REFERENCES

References: 

1.
Nalbantgi
l I. Angiotensin konverting enzim inhibitörleri. Istanbul, Tunç matbaacılık. 1989.
2.
Kayaal
p O. Peptid yapılı otokoidler ve antagonistleri. Tıbbi Farmakoloji 3. cilt. Ankara, Feryal Matbaacılık.1997.
3. Jaberansari MT, Baxter GF, Muller CA, Latouf SE.Angiotensin -converting enzyme inhibition enhances a subthreshold stimulus toelicit delayed preconditioning in pig myocardium.Am Coll Cardiol 2001;37:1996 -2001.
4. Maulik SK, Kumari R, Maulik M, Manchanda SC. Captopril and its time of administration in myocardial ischemic -reperfusion injury. Pharmacol Res 2001; 44:123.
5. Kayaalp
O
. Antihipertansif ilaçlar. Rasyonel tedavi yönünden Tıbbi farmakoloji 2. cilt 3. baskı. 1985. Ankara, Ulucan matbaası.
6. Huizer T, Weer P, Jong JW. Captopril inhibits an giotensin 1 -induced coronary flow reduction in isolated rat heart but has also no effect on contractility or energy metabolism. Eur Heart J 1992; 13:109.
7. Birincioglu M, Aksoy T, Olmez E, Acet A. Protective effect of ADE inhibitors on ischemia-reperfusion-induced arrhythmias in rats: Is this effect related to the free radical scavenging action of these drugs. Free Rad Res 1997; 27:389.
8. Opie L H. ACE inhibitors: Specific agent and pharmacokinetics. 1992. New York, A John Wiley&Sons inc. Publication.
9. Pasaoglu I, Bozer AY. Myokard korunması. Kalp hastalıkları ve cerrahisi. 1985. Ankara, Ayyıldız matbaası.
10. Anning PB, Grocott-Mason RM, Lewis MJ, Shah AM. Enhancement of left ventricular relaxation in the isolated heart by an angiotensin -converting enzyme inhibitor. Circulation 1985; 92: 2260.
11. Traquandi C, Riva E. Cardiac effects of sngiotensin I and angiotensin II: Dose response studies in isolated perfused rat heart. Pharmacol Res 1998; 37:57.
12. Gilst WH, Scholtens E, Graeff PA, Langen CD, Wesseling H. Differanti al
influances of angiotensin -converting enzyme inhibitors on the coronary circulation. Circulation 1988; 77, 124.
13. Gurevitch J, Pevni D, Frolkis I, Matsa M, Paz Y, Mohr R, Yakirevich V. Captopril in cardioplegia and reperfusion. Protective effects on the i schemic heart. Ann Thorac Surg 1997; 63, 627..
14. Wood JA, Hanley HG, Entman JL. Biochemical and morphological correlates of acute experimental myocardial ischemia in the dog. IV. Early mechanisms during very early ischemia. Circ Res 1979; 44:52.
15. Kirklin JW, Barratt-Boyes BG. Myocardial management during cardiac surgery with cardiopulmonary bypass. Kirklin JW, Barratt -Boyes BG, editors. 2, 129. 1993. New York, Churchill Livingstone Inc.
16. Bagchi D, Iyengar J, Stockwell P, Das DK. Enhanced prostaglandin product ion in the ischemic -reperfused myocardium by captopril linked with its free radical scavenging action. Prostaglandins Leukot Essenty Fatty Acids 1989; 38:145.
17. Zhang YH, Xu SC. Captopril cardioplegia on myocardial protection in the hypertrophied rat hearts. Int J Cardiol 1994; 47:131.

Thank you for copying data from http://www.arastirmax.com